



## Identification and Validation of New Biomarkers to Help the Creation of Clinical Diagnostics in Autoimmune and Cancer Diseases

Guest Editor:

**Dr. Veronique Demers-  
Mathieu**

Exagen Inc., 1261 Liberty Way,  
Vista, CA 92081, USA

Deadline for manuscript  
submissions:

**closed (31 May 2024)**

### Message from the Guest Editor

The identification of biomarkers in patients with immunological diseases, including cancer and autoimmune diseases, is critical to prevent disease progression, predicting the prognosis, targeting the appropriate therapeutic drugs and personalized medicine, and clinical decision-making processes involved in the diagnosis and assessment of disease. Measurement of biomarker proteins and signature protein expression specific to the disease and biological samples help to understand the mechanisms involved in the pathogenesis of these disorders. For cancer, immune-monitoring assays for immunosuppressive factors that prevent an effective antitumor immune response in tumor tissues and peripheral blood are necessary to improve immunotherapy strategies.

This Special Issue aims to focus on and describe the current development of research on new assays to identify and validate new biomarkers to enhance the creation of clinical diagnostics in autoimmune and cancer diseases.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI